TrialThe Lancet. Haematology2020

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Andrew M Brunner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.